Bioavailability & Solubility

MARKET BRIEF – Miniaturizing Healthcare – From Microelectronics to Nanobiosensing

Cecilia Van Cauwenberghe, MS, Technical Insights Senior Research Analyst, Frost & Sullivan, reports that the proliferation of lower cost microfluidics-based genomics tools offering improved capabilities and allowing more access to end-users is expected to drive this technology for pharmaceutical and biomedical research throughout the next 5 years.

EXECUTIVE INTERVIEW – Ascendia Pharmaceuticals: Sophisticated Formulations for Poorly Soluble Drugs

Jingjun (Jim) Huang, PhD, CEO, and Founder of Ascendia, discusses his company’s unique vision and strategy to provide pharmaceutical companies with a contract research partner that can provide technologies in order to efficiently determine which approach is most suitable for a given molecule.

EXCLUSIVE ONLINE CONTENT

6/6/2018

TxCell Names Lonza as its CAR-Treg Cellular Product Manufacturer

TxCell SA and Lonza Pharma & Biotech recently announced entering into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.